Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Extramedullary disease in plasma cell myeloma: the iceberg phenomenon

Bone Marrow Transplantation volume 48, pages 10–18 (2013)Cite this article

Subjects

Abstract

Extramedullary (EM) plasmacytomas (EMPs) that are not progression of intramedullary (IM) plasma cell myeloma (PCM) are usually indolent. In contrast, EM spread of IM PCM is associated with a poor prognosis. The recently introduced Durie-Salmon PLUS staging system includes EM disease in the poor prognosis category. One study noted an increase in EM disease both at diagnosis and during follow-up of PCM in 2000–2007 compared with previous years raising concerns that adoption of novel agents (thalidomide, lenalidomide and bortezomib) and greater use of hematopoietic cell transplantation (HCT) might be contributory to this. It is uncertain if this is a true increase or merely greater detection due to the increasing use of more sensitive imaging techniques (computerized tomography, magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography) or a reflection of the evolving natural history of PCM in an era when patients are living longer (median overall survival before 1996 was 29.9 months vs 44.8 months after 1996). Recent studies suggest there are important biological differences between PCM with or without EM spread that are offering clues that might explain the propensity for dissemination and a more aggressive clinical course. For example, EM relapse in PCM with and without deletion 13 was 30.8 vs 5.6%, suggesting the biology of a plasma cell subclone before HCT can affect the nature of the relapse after HCT. This article will explore the clinical, biological and treatment implications of EM spread of PCM. In addition, the impact of extramedullary disease on the outcomes of autologous and allogeneic HCT for PCM will be analyzed. Allogeneic HCT early in the course of high-risk PCM with EM disease is a consideration since graft vs myeloma effects may be essential to achieve maximal survival benefits.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcomes of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21: 325–330.

    Article  CAS  PubMed  Google Scholar 

  2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of lnovel therapies. Blood 2008; 111: 2516–2520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Durie BG . The role of anatomic and functional staging in myeloma: description of Durie/Salmon Plus staging system. Eur J Cancer 2006; 42: 1539–1543.

    Article  PubMed  Google Scholar 

  4. Durie BGM, Waxman AD, D’Agnolo A, Williams CM . Whole body F- FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–1463.

    PubMed  Google Scholar 

  5. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

    Article  Google Scholar 

  6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

    Article  PubMed  Google Scholar 

  7. Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B et al. Extramedullary plasmacytoma: tumor recurrence and therapeutic concepts. Cancer 1999; 85: 2305–2314.

    Article  CAS  PubMed  Google Scholar 

  8. Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C et al. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 2004; 73: 402–406.

    Article  CAS  PubMed  Google Scholar 

  9. Blade J, Lust JA, Kyle RA . Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12: 2398–2404.

    Article  CAS  PubMed  Google Scholar 

  10. Blade J, Kyle RA, Greipp PR . Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345–351.

    Article  CAS  PubMed  Google Scholar 

  11. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 2009; 50: 230–235.

    Article  CAS  PubMed  Google Scholar 

  12. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906–908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23: 1545–1556.

    Article  CAS  PubMed  Google Scholar 

  14. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E et al. Myeloma of the central nervous system: association with high risk chromosomal abnormalities, plamsablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117: 103–108.

    Article  PubMed  Google Scholar 

  15. De Larrea CF, Rosinol L, Cibeira MT, Rozman M, Rovira M, Blade J . Extensive soft tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol 2010; 85: 448–451.

    Article  PubMed  Google Scholar 

  16. Dawson MA, Patil S, Spencer A . Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143–144.

    Article  CAS  PubMed  Google Scholar 

  17. Alegre A, Granda A, Martinez-Chamorro C, Diaz-Mediavilla J, Martinez R, Garcia-Larana J et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002; 87: 609–614.

    PubMed  Google Scholar 

  18. Perez-Shimon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D et al. Reduced intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapse in multiple myeloma patients. Leukemia 2006; 20: 542–545.

    Article  Google Scholar 

  19. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M . Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004; 34: 1057–1065.

    Article  CAS  PubMed  Google Scholar 

  20. Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 2008; 41: 779–784.

    Article  CAS  PubMed  Google Scholar 

  21. Sheth N, Yeung J, Chang H . p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res 2009; 33: 1357–1360.

    Article  CAS  PubMed  Google Scholar 

  22. Chang H, Yeung J, Qi C, Xu W . Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous p53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138: 324–329.

    Article  CAS  PubMed  Google Scholar 

  23. Chang H, Sloan S, Li D, Stewart AK . Multiple myeloma involving central nervous system: high frequency of chromosome 17p 13.1 (p53) deletions. Br J Haematol 2004; 127: 280–284.

    Article  CAS  PubMed  Google Scholar 

  24. Kremer M, Ott G, Nathrath M, Specht K, Strecker K, Alexiou C et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol 2005; 205: 92–101.

    Article  CAS  PubMed  Google Scholar 

  25. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM . Possible roles for activating RAS mutations in MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.

    Article  CAS  PubMed  Google Scholar 

  26. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hallek M, Bergsagel PL, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.

    CAS  PubMed  Google Scholar 

  28. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S . Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011; 118: 675–678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harrousea JL, Bataille R et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spread, and immortalization. Cancer Res 1995; 55: 3647–3653.

    CAS  PubMed  Google Scholar 

  30. Dahl IM, Rasmussen T, Kauric G, Husebekk A . Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002; 116: 273–277.

    Article  CAS  PubMed  Google Scholar 

  31. Katz BZ . Adhesion molecules-The lifelines of multiple myeloma cells. Sem Cancer Biol 2010; 20: 186–195.

    Article  CAS  Google Scholar 

  32. Oliveira AM, Maria DA, Metzger M, Linardi C, Giorgi RR, Moura F et al. Thalidomide treatment down-regulates SDF-1 alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009; 33: 970–973.

    Article  CAS  PubMed  Google Scholar 

  33. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M et al. Bortezomib overcomes cell-adhesion mediated drug resistance through down regulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231–242.

    Article  CAS  PubMed  Google Scholar 

  34. Yata K, Yaccoby S . The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18: 1891–1897.

    Article  CAS  PubMed  Google Scholar 

  35. Hedvat CV, Comenzo RL, Teruya-Fedstein J, Olshen AB, Ely SA, Osman K et al. Insights into extramedullary tumor cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003; 122: 728–744.

    Article  CAS  PubMed  Google Scholar 

  36. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836.

    CAS  PubMed  Google Scholar 

  37. Nakazato T, Suzuki K, Mihara A, Sanada Y, Kakimoto T . Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous pleural effusion: remarkable response with a combination of thalidomide and dexamethasone. Intern Med 2009; 48: 1827–1832.

    Article  PubMed  Google Scholar 

  38. Gonzalez-Porras JR, Gonzalez M, Garcia-Sanz R, San Miguel JF . Thalidomide in combination with cyclophosphamide and dexamethasone (thalcydex) is effective in soft-tissue plasmacytomas. Br J Haematol 2002; 119: 883–884.

    Article  CAS  PubMed  Google Scholar 

  39. Biagi JJ, Prince HM . Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation. Br J Haematol 2001; 115: 484–485.

    Article  CAS  PubMed  Google Scholar 

  40. Mohty M, Stoppa AM, Blaise D, Ismardon D, Gastaut JA, Olive D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol 2002; 72: 939–945.

    CAS  PubMed  Google Scholar 

  41. Rosinol L, Cibeira MT, Martinez J, Mateos MV, Oriol A, Terol MJ et al. Thalidomide/dexamethasone vs bortezomib (velcade)/thalidomide/dexamethasone (VTD) vs VBMCP/VBAD/velcade as induction regimens prior to autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. Blood 2009; 114 Abstract 130.

  42. Paubelle E, Coppo P, Garderet L, Azizi L, Bories D, Gorin NC et al. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia 2005; 19: 1702–1704.

    Article  CAS  PubMed  Google Scholar 

  43. Calvo-Villas JM, Alegre A, Calle C, Hernandez MT, Garcia-Sanchez R, Ramirez G . Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 2011; 87: 281–284.

    Article  CAS  PubMed  Google Scholar 

  44. Study to determine efficacy and safety of lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide in patients with previously untreated multiple myeloma (FIRST). ClinicalTrials.gov NCT00689936.

  45. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  46. Zomas A, Stefanoudaki K, Fisfis M, Papadaki J, Mehata J . Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998; 21: 1163–1165.

    Article  CAS  PubMed  Google Scholar 

  47. Sun K, Welniak LA, Panoskaltsis-Mortari A, O’Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120–8125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005; 75: 376–383.

    Article  PubMed  Google Scholar 

  49. Liu YY, Patwardhan GA, Bhinge K, Gupta V, Gu X, Jazwinski SM . Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 2011; 71: 2276–2285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu YY . Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors. Cancer Res 2011; 71: 6295–6299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Bone Marrow Transplant Program, University of Florida, Gainesville, FL, USA

    B Wirk, J R Wingard & J S Moreb

Authors
  1. B Wirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J R Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J S Moreb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Wirk.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirk, B., Wingard, J. & Moreb, J. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant 48, 10–18 (2013). https://doi.org/10.1038/bmt.2012.26

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.26

Keywords

This article is cited by

Search

Advanced search

Quick links